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The bromodomain protein BRD4 regulates the
KEAP1/NRF2-dependent oxidative stress response
M Hussong1,2, ST Bo¨rno1, M Kerick1, A Wunderlich1, A Franz1,2, H Su¨ltmann3, B Timmermann4, H Lehrach1, M Hirsch-Kauffmann1
and MR Schweiger*,1,5
The epigenetic sensor BRD4 (bromodomain protein 4) is a potent target for anti-cancer therapies. To study the transcriptional
impact of BRD4 in cancer, we generated an expression signature of BRD4 knockdown cells and found oxidative stress response
genes significantly enriched. We integrated the RNA-Seq results with DNA-binding sites of BRD4 generated by chromatin
immunoprecipitations, correlated these with gene expressions from human prostate cancers and identified 21 top BRD4
candidate genes among which the oxidative stress pathway genes KEAP1, SESN3 and HDAC6 are represented. Knock down of
BRD4 or treatment with the BRD4 inhibitor JQ1 resulted in decreased reactive oxygen species (ROS) production and increased
cell viability under H2O2 exposure. Consistently, a deregulation of BRD4 diminished the KEAP1/NRF2 axis and led to a disturbed
regulation of the inducible heme oxygenase 1 (HMOX1). Without exogenous stress induction, we also found BRD4 directly
targeting the HMOX1 promoter over the SP1-binding sites. Our findings provide insight into the transcriptional regulatory
network of BRD4 and highlight BRD4 as signal transducer of the cellular response to oxidative stress.
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The permanent exposure of organisms to environmental
changes requires a variety of cellular adaption processes. The
response of cells to exogenous stressors, such as inflamma-
tion, xenobiotics, heat or ionizing radiation, is regulated by
multiple stress response pathways helping to maintain or
rearrange cellular homeostasis or to repair stress-induced
damage. The antioxidant defense following oxidative stress
injury activates signaling pathways such as the Nf-kB1 and the
Kelch-like ECH-associated protein 1 (KEAP1)/NRF2 (nuclear
factor, erythroid 2-like 2, NFE2L2) pathway2 that can promote
cell survival or apoptosis.
Within the KEAP1/NRF2 pathway, KEAP1 senses electro-
philic and oxidative stress and functions as a substrate
adapter protein for the E3 ubiquitin ligase complex. The
transcription factor NRF2, when bound to KEAP1, is a highly
unstable protein that is polyubiquitinated and targeted for
selective degradation via the ubiquitin proteasome pathway.2–4
Upon stress, induced by diverse stimuli – including reactive
oxygen species (ROS), heme or metalloporphyrins – reactive
cysteine residues of KEAP1 become modified, which alters
the structural integrity of the KEAP1–Cul3 E3 ligase complex.
As a result, NRF2 escapes from KEAP1-dependent degrada-
tion and accumulates in the nucleus.2,5,6 Here, NRF2
acts as transcriptional activator of cytoprotective genes.
NRF2-regulated genes are involved in glutathione synthesis,
such as glutathione S-transferase Pi7,8 and in the elimination
of ROS, facilitated by superoxide dismutases (SOD) and
heme oxygenase 1 (HMOX1).9 In humans, the KEAP1/NRF2
pathway is frequently disrupted in lung cancer.10–12
We have found the KEAP1/NRF2 stress response to be
regulated by bromodomain-containing protein 4 (BRD4).
Early on, the bromodomain protein BRD4 has been implicated
in transcriptional regulation processes.13–15 BRD4 interacts
with the positive transcriptional elongation factor b and
promotes the phosphorylation of RNA polymerase II.16,17
Recent work has also discovered that BRD4 binds to the
so-called ‘super-enhancers’.18 Super-enhancers are charac-
terized by a large size, high transcription factor density and
content and increased binding of the Mediator complex.19 In
multiple myeloma (MM), for example, super-enhancers are
approximately 15-fold larger and have a 16–18-fold increase
in Mediator and BRD4 binding in comparison to regular
enhancers. They are also frequently associated withMYC and
other tumor-specific genes.18
These mechanisms might all contribute to the discovery of
BRD4 as a valuable drug target in many tumor entities,
including leukemia, lung cancer, MM and melanoma.20–23
However, to date the exactmechanism of BRD4 inhibition as a
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powerful anti-cancer treatment is still unclear. Here, we show
that BRD4 is a regulator of KEAP1 transcription. Downstream
of KEAP1, NRF2 coordinates the induction of HMOX1 as well
as other oxidative stress-related genes, and alterations in
BRD4 expression result in a de-regulated oxidative stress
response answer. This regulatory function is disrupted in
prostate cancer and thus might have a central role in
malignant processes.
Results
Identification of BRD4-regulated genes in prostate
cancer. In a systems biological approach, we have pre-
viously generated gene expression profiles from 48 normal
and 47 tumor prostate tumor tissue samples.24 Here, gene
expression analyses of BRD4 revealed a significant increase
of BRD4 in our prostate tumor samples (Supplementary
Figure S1a). To investigate which BRD4 target genes are
most significantly de-regulated in cancer, we first aimed to
identify BRD4 target genes. We therefore generated RNA-
Seq expression data of two BRD4 knockdown experiments in
HEK293T cells and integrated it with BRD4 DNA-binding
results gained by two BRD4 chromatin immunoprecipitation
(ChIP)-Seq experiments (Figure 1a). In gene expression
analyses, we identified 1844 genes significantly differentially
regulated (log2FC4±0.4) in both RNA-Seqs with mean
log2FC4±0.5 (Supplementary Table S1). Of these, 970
were upregulated – and 887 were downregulated. We
focused our further analyses on the 887 downregulated
genes to elucidate a potential direct transcriptional activating
role of BRD4. With BRD4 ChIP experiments, we identified
1885 significant BRD4-binding site peaks (FDRo5%) when
combining enriched peaks of our two ChIP-Seq experiments.
We annotated genes with a BRD4-binding site within 0.5 kb
of the transcription start site (TSS) (Supplementary Table
S2). Integration of both gene lists – the data obtained by the
RNA-Seq and ChIP-Seq experiments – resulted in 52
commonly activated genes of BRD4, now considered as
our top candidate target genes (Supplementary Table S3).
Further, we selected genes from our prostate tissues gene
expression profiles with correlations to BRD4 expres-
sion40.4 (Figure 1b). Out of our 52 BRD4 target genes, we
identified 21 genes with positive correlations to BRD4 in
prostate cancer (Supplementary Table S4). We termed them
cancer-relevant BRD4 target genes. Interestingly, among
these, three were involved in themaintenance of physiological
concentrations of intracellular ROS: SESN3 (sestrin 3),
HDAC6 (histone deacetylase 6), and KEAP1. These and
two additional genes (MAPK3 and VIM) were validated in
independent ChIP-quantitative PCR (qPCR) experiments in
DU-145 prostate cancer cell lines (Figure 1c).
KEAP1 is a transcriptional target of BRD4 and a gate-
keeper of the oxidative stress response in cancer. The
KEAP1/NRF2 interplay, mediator of one of the major
oxidative stress response pathways, is frequently disturbed
by somatic mutations in many cancer entities.12,25 We found
KEAP1 upregulated in prostate cancer and highly correlated
with BRD4 (Figure 1d and Supplementary Figure S1b). To
see whether the oxidative stress response pathway in
general is affected by BRD4, we used a list of oxidative
stress responsive genes (Gene Ontology, GO:0034599,
‘cellular response to oxidative stress’) and performed an
enrichment analysis in the BRD4 knockdown experiment
(Supplementary Table S1). Indeed, we found a significant
enrichment of these genes indicating a functional role of
BRD4 in the defense against oxidative stress (OR¼ 3.9;
P-value¼ 2.7 10 5, Supplementary Table S5). Besides
the KEAP1/NRF2 pathway, we also found other stress-
responsive pathways affected by BRD4 knockdown, albeit to
a lower degree (Table 1).
Next, we asked which genes of the oxidative stress
response were most significantly de-regulated by BRD4
depletion. Besides transcriptional regulators, such as PML,
TP53 and MDM2, we found genes coding for enzymes of the
antioxidant system, including CAT (catalase), SOD2 (super-
oxide dismutase 2) and GPX1 (glutathione peroxidase 1).
These genes are predominant targets of NRF226,27 and were
all significantly downregulated upon BRD4 knockdown. This
was a somewhat unexpected result, because knock down of
BRD4 decreased KEAP1 and should result in an increase of
NRF2 and its target genes. Besides CAT, SOD2 and GPX1,
the inducible enzyme HMOX1 is one of the best investigated
targets of the NRF2/KEAP1 pathway. Although due to
incongruent results not part of our initial RNA-Seq
candidate list, we also found HMOX1 de-regulated
after BRD4 knockdown by western blotting (Figure 1e) and
qPCR (Supplementary Figure S2a) experiments. Thus,
both – KEAP1 as well as HMOX1 (and other NRF2 target
genes) – were significantly downregulated after BRD4 knock-
down, demonstrating their dependence on BRD4.
Interestingly, when we investigated the expression levels of
BRD4, KEAP1, NRF2 and HMOX1 in three prostate cancer
cell lines (DU-145, LNCAP and PC3), we found a significant
upregulation of BRD4 and KEAP1 and a downregulation of
NRF2 in all cell lines (Figure 1f). In contrast, HMOX1 was
upregulated in DU-145, downregulated in PC3 and not altered
in LNCAP cells, again showing that a downregulation ofNRF2
not necessarily results in a low expression of HMOX1. Thus,
we were now wondering whether this is also consistent after
HMOX1 induction.
BRD4 knockdown increases the induction of HMOX1
after cobalt protoporphyrin (CoPP) stimulation through
enhancing the NRF2 DNA-binding affinity. HMOX1
expression is inducible by various stimuli, including metallo-
porphyrins, such as CoPP. Having observed that BRD4
knockdown in unstressed cells significantly repressed
KEAP1 and HMOX1 expression, we asked whether BRD4
influences the CoPP-mediated induction of HMOX1. Indeed,
BRD4 knockdown experiments in combination with CoPP
induction showed that, under these conditions, a reduced
BRD4 level resulted in an elevated HMOX1 expression in a
time-dependent manner of CoPP stimulation (Figure 2a). To
get further insight into the effect of BRD4 on the CoPP-
mediated induction of HMOX1, we transfected cells with a
BRD4 overexpression plasmid and analyzed the HMOX1
expression after stimulation with varying concentrations of
CoPP. In this case, the overexpression of BRD4 led to an
attenuated activation of HMOX1 RNA expression compared
BRD4-dependent regulation of KEAP1/NRF2
M Hussong et al
2
Cell Death and Disease
Figure 1 BRD4 target genes are significantly over-represented in prostate cancer. (a) Flow diagram illustrating the integration of RNA-Seq, ChIP-Seq and correlation
analyses of genome-wide gene expression patterns in prostate tissues for the identification of target genes of BRD4. (b) Integration of differential gene expression data
obtained by RNA-Seq of BRD4 knockdown experiments and correlation data of BRD4 in 95 primary prostate tumor and normal tissue samples. The ordinate shows the
log2(ratios) of BRD4 knockdown versus control in HEK293T cells. The abscissa depicts the Spearman correlation values of BRD4 expression to the expression of each gene in
tumor and normal prostate samples measured by gene expression arrays.24,59 Putative BRD4 target genes with a log2(ratio) of below  0.4 and a mean log2(ratio) below
 0.5 in both cell line experiments (Supplementary Table S1) that we also found in our BRD4 ChIP-Seq analyses are highlighted by a square. Circles mark putative targets
additionally exhibiting a positive correlation of4þ 0.3 between BRD4 and the gene candidate in prostate samples. Dotted horizontal lines denote log2(ratio) values of 0.4
and 0.4 while vertical lines represent correlation thresholds of 0.3 and 0.3. KEAP1 is marked by an asterisk (*). (c) ChIP validations of BRD4 binding in DU-145 cells to the
indicated promoters using region-specific primer and an intergenic NCR as negative control. (d) Correlation between KEAP1 and BRD4 in prostate samples (gray¼ normal,
black¼ tumor; Rho¼ 0.74). The boxplots on the right side of the plot show the differential expressions between tumor (n¼ 47) and normal samples (n¼ 48) of KEAP1
(Mann–Whitney P-valueo4.7 10 12). (e) Western blot of BRD4, HMOX1 and KEAP1 after BRD4 knockdown. HEK293T cells were transfected with either shBRD4 or a
control shRNA (shControl) and harvested 72 h post transfection. As loading control b-actin (ACTB) and a-tubulin (TUBB) were used. (f) BRD4, KEAP1, NRF2 and HMOX1
mRNA expression in prostate cancer cell lines using qPCR. The expression was determined in at least two independent experiments
Table 1 Enrichment of stress response pathways in BRD4 knockdown RNA-Seq experiments
GO number GO name BRD4 KD Data set Odds ratio P-value
GO:0034599 Cellular response to oxidative stress 16 70 3.88 2.3 10 5
GO:0006970 Osmotic stress response 11 61 2.87 3.7 10 3
GO:0010038 Response to metal ion 32 285 1.66 0.01
GO:0009408 Response to heat 5 64 1.10 0.81
GO:2001020 DNA damage response 4 82 0.66 0.52
GO:0050727 Inflammatory response 27 162 2.63 3.75 10 5
GO:0034976 Response to ER stress 14 135 1.50 0.18
GO:0001666 Response to hypoxia 24 255 1.35 0.18
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with the corresponding mock control (Supplementary Figure
S3a). To explore whether the enhanced induction of HMOX1
by BRD4 knockdown after stimulation was due to an increase
in NRF2 caused by a decreased KEAP1 protein level (as
already seen after BRD4 knockdown), we treated HEK293T
cells (þ /BRD4 knockdown) with 20 mM CoPP and
analyzed the endogenous NRF2 protein level at different
time points. NRF2 increased in a time-dependent manner
after CoPP induction in the control BRD4 cells, but,
interestingly, NRF2 was even more increased in the BRD4
knockdown cells after CoPP treatment (Figure 2b). The
increased NRF2 level was not due to an increased
transcriptional activity (Supplementary Figure S3b). As
expected, we found KEAP1 downregulated with and without
stress (Supplementary Figure S3c). In addition, we found an
increased nuclear accumulation of NRF2 in BRD4 knock-
down cells under CoPP treatment compared with the control
cells (Figure 2c). To further investigate whether the
increased NRF2 accumulation also resulted in an enhanced
DNA binding of NRF2, we performed ChIP experiments in
CoPP-treated and -untreated BRD4 knockdown cells. NRF2
binds to antioxidant-responsive elements and NF-E2/Maf-
recognition elements, respectively, that are mainly found in
the enhancer regions E1 and E2, locatedB3 kb andB10 kb
upstream of the transcription-initiation site.3,28 We tested the
NRF2 enrichment on both HMOX1 enhancers as well as on
the promoter region, which was used as negative control.
Actually, BRD4 reduction significantly increased NRF2
binding to both HMOX1 enhancers after CoPP induction
(Figure 2d). Further functional experiments demonstrated a
low level of BRD4 to be advantageous for cells under stress:
We treated control cells as well as cells with BRD4
knockdown with hydrogen peroxide (H2O2) and measured
cell survival over 72 h. Accordingly, cells with diminished
BRD4 expression displayed an increased cell survival upon
H2O2 treatment compared with control cells (Figure 2e).
The BRD4 inhibitor JQ1 reduces ROS and increases cell
survival upon oxidative stress. The upregulation of
HMOX1 protects cells against increased levels of ROS and
consequently against oxidative stress-mediated cell death.
Hence, we tested whether the increased HMOX1 induction in
Figure 2 BRD4 regulates the stress-mediated expression of HMOX1. (a) HEK293T cells were transfected with either shBRD4 or shControl and stimulated with 20 mM of
CoPP for 6, 10 and 14 h for western blot analysis (left) or 2, 4, 6 and 10 h for qPCRs with tubulin as reference gene (right). (b) Western blot analysis of the NRF2 expression
after CoPP treatment. NRF2 (star) protein levels were measured after treatment with 20 mM CoPP in BRD4 knockdown cells (shBRD4) or control cells (shControl) after 6, 10
and 14 h, as indicated. Tubulin (TUBA) was used as a loading control. (c) Immunofluorescence of NRF2 after CoPP stimulation. WI-38 cells were transfected with either
shBRD4 or a control shRNA (shControl) and treated with 50mM CoPP or DMSO for 6 h. After 72 h, cells were stained with antibodies against NRF2 and Hoechst and
examined with a confocal fluorescence microscope (LSM 510 meta, Zeiss). (d) ChIP analyses of the NRF2 binding to enhancer regions of the HMOX1 promoter. ShBRD4
knockdown or shControl cells were treated with 50mM CoPP or DMSO for 6 h. The NRF2 binding to the HMOX1 promoter as well as to both enhancers was analyzed with
qPCRs using region-specific primers. (e) Cell viability assay of BRD4 knockdown. WI-38 cells were transfected either with siBRD4 or non-targeting control siRNA. After 24 h,
cells were treated with 100mM H2O2 for 30 min. Cell viability was measured after 24, 48 and 72 h using the Alamar Blue reagent
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BRD4 knockdown resulted in a decreased ROS level and an
enhanced cell survival. For these experiments, we used the
bromodomain and extra-terminal (BET) inhibitor JQ129 and
measured the expression level of KEAP1. Similar to the
BRD4 knockdown experiments, we found a downregulation
of KEAP1 in a dose-dependent manner upon JQ1 treatment
(Figure 3a). We also measured the cell viability of cells
treated with and without JQ1 under oxidative stress condi-
tions. These experiments confirmed our observation of a
decreased cell death after oxidative stress induction in cells
with an inhibited BRD4 function (Figure 3b). Next, we
investigated the level of ROS in cells with diminished BRD4
activity with and without H2O2 addition. We used a
dihydrorhodamine 123 (DHR) flow cytometry assay and
observed, after H2O2 treatment, a significant reduced
number of cells with high levels of ROS in JQ1-treated cells
compared with the dimethyl sulfoxide (DMSO) control
(Figures 3c and d). Thus, the inhibition of BRD4 lowers
intracellular ROS levels after exposure to stress, which might
be the explanation for the increased cell viability (Figure 3b).
Furthermore, we also measured the amount of ROS in the
prostate cancer cell line DU-145. As we had observed a
significant upregulation of BRD4 in DU-145 cells (Figure 1f),
we expected an increased ROS production in these cells upon
H2O2 treatment. Indeed, we detected a slight increase in ROS
levels in the DU-145 cell line in comparison to the cell line
RWPE-1, a cell line derived from normal prostate tissue (data
not shown). Nevertheless, a treatment with JQ1 inhibitors in
DU-145 cells did not result in a shift towards lower ROS
concentrations. This was also mirrored by cell viability assays
upon JQ1 treatment. In these experiments, the prostate
cancer cell line DU-145 seemed to be resistant against JQ1,
further supporting a diminished KEAP/NRF2 axis in DU-145
cells.
BRD4 activates HMOX1 expression over specificity
protein 1 (SP1) binding sites in the absence of stress.
During our effort to clarify the regulatory role of BRD4 in the
oxidative stress KEAP1/NRF2 response pathway, we have
observed that a diminution of BRD4 leads to an increased
production of the inducible HMOX1 after stimulation with
CoPP. The situation in an uninduced state was different:
A BRD4 knockdown resulted in a decreased HMOX1 level.
To further analyze this discrepancy, we performed luciferase
reporter assays in the absence of stress. HMOX1 expression
is regulated over several transcriptional regulatory elements
and transcription factor binding sites and enhancer regions
E1 and E2 located upstream of the HMOX1 promoter region.
We generated different luciferase constructs that either
contained the enhancer region 1 in addition to a 2-kb region
of the HMOX1 promoter (E1-HMOX1-WT (wild type)) or
fragments of different sizes of the promoter region alone
(HMOX1-WT, HMOX1-367, HMOX1-228) (Figure 4a). An
overexpression of NRF2 showed the expected increase of
the luciferase signal with E1-HMOX1-WT but not with
HMOX1-WT, confirming the transcriptional enhancement by
Figure 3 BRD4 inhibition decreases ROS and enhances cell survival under oxidative stress. (a) KEAP1 mRNA expression was analyzed in WI-38 cells after 72 h of JQ1 or
DMSO treatment using qPCR. As a reference gene, b-tubulin was used. The results represent the averages of two independent experiments. (b) WI-38 cells were incubated
with various concentrations of JQ1 for 72 h. Twenty-four hours before determination of cell viability, the cells were treated with 100mM H2O2 for 30 min. (c) Determination of
ROS in WI-38 cells. Cells were treated with 1mM JQ1 or DMSO for 72 h. Four hours before detection, 1 mM H2O2 was used to stimulate ROS production. The intensity of
intracellular ROS was measured using the fluorescence substrate DHR. Cells with high levels of ROS are shown in light grey, whereas the dark grey points represent cells with
low ROS levels. Percentages indicate the relative amount of cells with high ROS levels. (d) Flow cytometry analysis using the Flowing Software 2 in cells treated with various
concentrations of JQ1. The distribution of cells with high and low intensity of DHR was calculated and plotted as relative cell number. Low intensity of DHR represents low level
of ROS, whereas high fluorescence indicates high level of ROS. (*P-valueso0.05 and **P-valueso0.01 according to two-tailed t-tests)
BRD4-dependent regulation of KEAP1/NRF2
M Hussong et al
5
Cell Death and Disease
NRF2 through the enhancer regions (Figure 4b). Interest-
ingly, a co-transfection with BRD4 only marginally increased
the reporter activity of the E1-HMOX1-WT construct but
instead showed an enhanced luciferase activity with the
HMOX1-WT promoter construct. This suggests an additional
transcriptional regulation mechanism of HMOX1 through
BRD4 besides the KEAP1/NRF2 pathway. A BRD4 knock-
down significantly decreased the promoter activity of the
HMOX1-WT construct to nearly 60% (Figure 4c). To
investigate whether BRD4 directly activates the HMOX1
transcription by direct association to the promoter, we
performed a ChIP experiment with an a-BRD4 antibody.
QPCR analyses showed that the HMOX1 promoter, but not
the NCR (non coding region), was42-fold increased in the
BRD4 ChIP (Figure 4d).
To elucidate how BRD4 may regulate the HMOX1
promoter, we shortened the HMOX1 promoter to curtail the
regulatory elements. Using 367- and 228-bp long reporter
constructs, we found the activating function of BRD4
independent of the NF-kB site (230–250 bp upstream of the
TSS) (Figure 5a).30 To identify BRD4 consensus-binding
motifs, we used the binding regions identified from our ChIP-
Seq experiments and performed bioinformatics analyses.31
This resulted in the SP1-binding motif as one of our top
candidates for BRD4 binding (Figure 5b, Supplementary
Table S6).
We inserted SP1-binding site point mutations in the
HMOX1-WT luciferase reporter plasmid and tested the
promoter activity following BRD4 overexpression (Figure 5c).
The mutation significantly abolished the transcriptional activa-
tion function of BRD4 by 50%.
Our experiments strongly suggest a regulation of HMOX1
by BRD4, even independent of the KEAP1/NRF2 pathway,
through the direct association to the SP1-binding motif in the
HMOX1 promoter.
Discussion
BRD4, an acetylated histone-binding protein, has been
identified as an important factor for the regulation of primary
response and interferon-stimulated gene expression.30–34
Furthermore, BRD4 seems to have a complex role in the
transcriptional program of different tumor entities. On the one
hand, studies in colorectal and breast tumors suggest BRD4
to act as a tumor suppressor.35,36 On the other hand, an
overexpression of the short BRD4 isoform results in increased
metastasis formation in breast tumors.37 Becoming aware of
BRD4 as a turnstile in tumor pathogenesis, understanding the
molecular mechanism of BRD4 action can help to shed light
on the complex de-regulated transcription machinery and to
identify central cancer pathways. Here we used an integrated
analysis of data from ChIP-Seq, RNA-Seq and gene
Figure 4 BRD4 regulates the transcription of HMOX1 in the absence of an inductor. (a) Schematics of the HMOX1 luciferase reporter constructs. (b) HMOX1 reporter
assays with BRD4 and NRF2. BRD4 (pcDNA-BRD4-FL), NRF2 (pTL-FlagC-NRF2) expressing constructs or empty vectors (EV) were co-transfected with a luciferase reporter
plasmid carrying the HMOX1 promoter either with (E1-HMOX1-WT) or without (HMOX1-WT) the first enhancer region of the HMOX1 gene. After 24 h, the cells were harvested
for luciferase analysis. The promoter activity was normalized to EVs and co-transfected renilla luciferase activity. The results represent the averages of three independent
experiments (*P-valueso0.05 and **P-valueso0.01 according to two-tailed t-tests). (c) HMOX1 reporter experiments with BRD4 knockdown. HEK293T cells were
co-transfected with either shBRD4-1, shBRD4-2 or shControl as control with the luciferase reporter carrying the HMOX1 promoter (HMOX1-WT). Seventy-two hours
post transfection, the cells were harvested for measuring the luciferase activity or for western blot analysis. The activity was normalized to the renilla luciferase activity and
transfections with an empty reporter construct. These results were confirmed by two biological replicates. Expression of BRD4 was measured with a western blot where tubulin
was used as a loading control. (d) Binding of BRD4 to the HMOX1 promoter. ChIP analyses were performed with antibodies against BRD4 or with rabbit IgG as a negative
control. The enrichment was analyzed with qPCRs for the promoter region of HMOX1 and an intergenic NCR. Values were normalized to the input and IgG controls
(*P-valueso0.05 and **P-valueso0.01 according to two-tailed t-tests)
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expression correlation analyses of primary prostate normal
and tumor tissue samples to nominate 21 key BRD4 target
genes in cancer.
Searching for possible common biological functions among
these genes, we compared our list with the regions published
by Loven et al.18 and found for eight genes an enhancer region
within the TSS. Interestingly, three of these genes are
involved in the maintenance of physiological concentrations
of ROS: SESN3, HDAC6 and KEAP1. De-regulation of the
intracellular ROS homeostasis can have fatal consequences
for the organism, including the development of cancer,
neurodegenerative diseases, rheumatoid arthritis, diabetes
and inherited syndromes, such as Fanconi anemia.38–40
In the absence of stress, we noticed that BRD4 activates
the HMOX1 promoter and regulates the HMOX1 expression
over the SP1 promoter-binding sites (Figure 6a). Thus, BRD4
acts as a positive transcriptional activator ofHMOX1, whereas
BRD4 silencing results in decreased HMOX1 mRNA and
protein expression as well as a reduced promoter activity
(Figure 6b). This may be a mechanism for a fast fine-tuning of
the cellular reactions towards small ROS deviations that do
not activate the KEAP1/NRF2 oxidative stress response.
However, we also identifiedKEAP1 as one of our top 21 BRD4
target genes. BRD4 binds to the KEAP1 promoter not only in
normal but also in prostate cancer cells, highlighting KEAP1
as activating direct target for BRD4 in cancer.
Under CoPP treatment, and thus exertion of stress, NRF2 is
significantly increased, which drives HMOX1 expression
(Figure 6c). An additional BRD4 knockdown further enhances
this mechanism by a downregulation of KEAP1 and a lack of
NRF2 degradation (Figure 6d). The increase in HMOX1 goes
along with an increased cell viability and a decreased amount
of intracellular ROS under H2O2 stress and a decreased
BRD4 function. Thus, under exertion of stress, BRD4’s
regulation of HMOX1 is mediated via the KEAP1/NRF2
pathway resulting in a counteraction of BRD4 and HMOX1
levels.
The KEAP1/NRF2 pathway is frequently disrupted by
somatic mutations in tumors. NRF2-activating somatic muta-
tions have been described in lung, head and neck, esophagus
and skin cancers.41,42 Mutations in NRF2 and KEAP1 are
clustered within the KEAP1–NRF2-binding surface43 but are
mutually exclusive. KEAP1 mutations are found, next to
abnormally increased DNA methylation, to impair KEAP1
function,44–46 thus liberating NRF2 to the nucleus.43 The
increased activity of NRF2 in tumors, in turn, can promote
ROS detoxification and tumorigenesis by conferring a more
reducing intracellular environment.47 HMOX1, the rate-limit-
ing enzyme in the heme catabolism and part of the cellular
defense against oxidative stress, is, similar to NRF2,
recognized as resistance mechanism against tumor necrosis
factor-induced cell death as shown in acute myeloic leukemia
(AML).48 Interestingly, in prostate cancer the block of the
KEAP1/NRF2 pathway seems to be located even down-
stream of NRF2: We showed that in prostate cancer tissues,
as well as in a subset of prostate cancer cell lines, HMOX1 is
upregulated irrespective of NRF2. In this case, a treatment
with JQ1 did not decrease ROS levels and did not lower cell
viability as one would have expected owing to the high BRD4
levels in these cells. Similarly, Wyce et al.49 found that IC50
values for the BET inhibitor I-BET762 for DU-145 cells
were43 mM, whereas for LNCaP cellso30 nM, supporting a
therapy resistance of DU-145 cells. As our measurement of
HMOX1 was done without exogenous stress, BRD4 might
have bypassed the KEAP1/NRF2 pathway and directly
regulated the HMOX1 promoter, as we have shown it in a
cell culture model in absence of stress. As far as HMOX1 is
concerned, Alaoui-Jamali et al.50 described a significant
Figure 5 BRD4 regulates HMOX1 over the SP1-binding motif. (a) Mapping of
the BRD4 activating region on the HMOX1 promoter. BRD4 (pcDNA-BRD4-FL) or
empty vector (EV) were co-transfected with a luciferase construct carrying the full-
length HMOX1 promoter (HMOX1-WT), a 367-bp long (HMOX1-367) or a 228-bp
(HMOX1-228) long fragment of the HMOX1 promoter. Twenty-four hours
post transfection, the cells were harvested, and the promoter activity was
determined and normalized to the renilla luciferase and the EV signals. The results
represent the averages of three independent experiments (*P-valueso0.05
according to two-tailed t-tests). (b) MEME analyses of BRD4 ChIP-Seq data.
The binding matrix represents the identified BRD4 ‘binding motif’ of the
ChIP-Sequencing. Using the TOMTOM analysis tool, the SP1-binding motif was
identified as one of the top known binding motifs associated with the BRD4-binding
site (P-value: 0.00026, E-value: 0.2305; q-value: 0.1024). At the right, the
SP1-binding site in the HMOX1 promoter (HMOX1-WT) and the used mutation
(HMOX1-SP1-mut) are shown. (c) Reporter assays with wild-type (HMOX1-WT) or
SP1-site-mutated (HMOX1-SP1-mut) HMOX1 reporter constructs. BRD4 and SP1
(pTL-FlagC-SP1) expressing constructs were co-transfected with either the HMOX1
wild-type promoter or with the SP1-binding site mutant. Twenty-four hours post
transfection, the cells were harvested, and the promoter activity was determined
and normalized to the renilla luciferase signal. The results represent the average of
two independent experiments (*P-valueso0.05 according to two-tailed t-tests)
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elevation of HMOX1 levels in hormone-refractory prostate
cancer and silencing of the HMOX1 gene or exposure to a
small molecular HMOX1 inhibitor (OB-24) reduced cell
proliferation, tumor growth and metastatic invasion. Having
this all in mind, one may speculate that a high BRD4 level in
combination with a high amount of HMOX1 might be an
indicator for BET inhibitor resistance. Vice versa, the classic
fields of application for BET inhibitors (e.g., JQ1, I-BET29,51)
so far are AML, MLL, MM and melanoma. Abrogation of
BRD4’s function results in a delayed tumor progression,
survival benefits, loss of stem cell characteristics and a
reduction of MYC oncogene expression. Searching the
Oncomine database, we found for AML and MM significantly
decreased HMOX1 expressions. Thus, the effective treat-
ment of AML and MM patients with BET inhibitors may – at
least partly – be supported by low HMOX1 levels.
Taken together, our data provide new insight into the
transcriptional regulatory network of BRD4 as it nominates
BRD4 as key mediator of KEAP1 in the oxidative stress
response and to directly target SP1-binding sites in the
HMOX1 promoter (Figure 6). In prostate tumors, these
regulatory mechanisms appear to be disturbed. The
increased BRD4 and KEAP1 expression in prostate cancer
does not go along with decreased HMOX1 levels. In contrast,
HMOX1 seems to be upregulated independently of the
KEAP1–NRF2 pathway (Figure 6), suggesting that the strong
increase in BRD4may, over a direct regulation of the HMOX1
promoter, counteract the downregulation of HMOX1 via
KEAP1-NRF2. The two-sided regulatory mechanism of
BRD4 may prevent tumor cells from a loss of HMOX1, an
increase of ROS and promote cell survival. As outlined above,
further studies of the BRD4 transcriptional network and the
cooperation between BRD4, KEAP1, NRF2 and NRF2 target
genes as transcriptional regulators in prostate cancer have
the potential to elucidate important druggable oncogenic
dependencies.
Materials and Methods
Plasmids, RNA interference, site-directed mutagenesis and
antibodies. The BRD4 shRNA knockdown vectors (shBRD4-1, shBRD4-2)
and the control vector have been described previously in Schweiger et al.52 The
siRNA-BRD4-pool (siBRD4) as well as the non-targeting control pool (siControl)
were purchased from Thermo Scientific (Schwerte, Germany). The pcDNA4c-
plasmid containing the full-length human BRD4 has been described previously in





Figure 6 Schematics of the regulation of the HMOX1 expression under normal (a and b) and stress conditions (c and d) and without (a and c) or with (b and d) BRD4
knockdown. Under normal conditions, BRD4 directly activates the HMOX1 promoter over SP1-binding sites. In the presence of stress, HMOX1 expression is mainly regulated
over the NRF2/KEAP1 pathway where BRD4 regulates KEAP1. The table summarizes the regulation of HMOX1 under varying BRD4 concentrations
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SP1-rev: 50-GAATGCGGCCGCTCAGAAGCCATTGCCACTGATA-30.
For the luciferase reporter assay, the HMOX1 promoter was cloned into the
pGL3-basic vector from Promega (Mannheim, Germany). The following primers





The enhancer region E1 was cloned into the BamH1 and SalI restriction sites in
the pGL3-basic vector using the primers HMOX1-E1fw: 50-ACAATTGGCCCAGTCT
ATGG-30 and HMOX1-E1rev: 50-GGAGTTCAAGACCAGCCTGA-30. The SP1-
binding site mutation in the HMOX1 promoter was created with the QuikChange II
Site-Directed Mutagenesis Kits (Agilent, Santa Clara, CA, USA) according to the
manufacturer’s protocol.
The following antibodies were used: rabbit polyclonal BRD4 antibody (ab75898,
Abcam, Cambridge, UK), mouse monoclonal HMOX1 antibody (ab13243, Abcam),
NRF2 (sc13032, sc722, Santa Cruz Biotechnology, Heidelberg, Germany), KEAP1
(K2769, Sigma-Aldrich, Taufkirchen, Germany), alpha-tubulin (T9026, Sigma-
Aldrich), and beta-actin (Cell Signaling, Leiden, Netherlands).
Luciferase reporter assay. The luciferase construct or the corresponding
negative control (pGL3-basic vector) were transfected together with a BRD4,
NRF2 or SP1 expression construct or shRNA plasmids. Luciferase activities were
measured 24 h after transfection for overexpression or 72 h after knockdown
approaches according to the manufacturer’s protocol (Dual-Luciferase Reporter
Assay System from Promega). Luciferase activities were normalized to the
luciferase activity of a co-transfected renilla expression plasmid.
Cell culture, CoPP treatment and transfection. Cells were cultivated
at 37 1C with 5% CO2 in their specific cell culture medium (Hek293T and DU-145:
Dulbecco’s Modified Eagle’s Medium, WI-38: Minimal essential Medium containing
10% fetal calf serum, 2 mM L-glutamine and 100 U penicillin/streptomycin and
RWPE-1: keratinocyte serum-free medium supplemented with EGF and BPE).
Cells were treated with 20–100mM CoPP (dissolved in DMSO) for 4–14 h and with
various concentrations of JQ1 (Cayman Chemical: 1268524-70-4, Ann Arbor, MI,
USA) for 72 h. Plasmids were transfected into the cells using X-treme gene 9
transfection reagent (Roche, Penzberg, Germany) and siRNA using HiPerFect
transfection reagent (Qiagen, Hilden, Germany).
Cell viability assay. Cell viability was measured using the Alamar Blue reagent
from Life Technologies (Darmstadt, Germany). Cells were seeded in 96-well plates
and treated with siRNAs or JQ1 inhibitor. After incubation for 72 h at 37 1C, 10ml of
Alamar Blue cell viability reagent was added according to manufacturer’s instructions,
and the resulting fluorescence intensity was read on the fluorescence spectrometer
LS55 (Perkin Elmer, Waltham, MA, USA).
ROS detection using flow cytomery. Cells were seeded in 12-well
plates and treated with siRNAs or JQ1 inhibitor at various concentrations. After
incubation for 72 h, 10mM DHR or 10mM DHRþ 1 mM H2O2 was added for
additional 4 h to determine the levels of oxidative stress products. The absorbance
of the green fluorescent rhodamine 123 was measured using an ACCURI C6
cytometer and analyzed with the Flowing Software 2 (BD Bioscience, San Jose,
CA, USA).
Protein extraction, western blot analysis and immunofluores-
cence. Cells were harvested and resuspended in 300ml lysis buffer
A (10 mM Hepes-KOH (pH 7.4), 10 mM NaCl, 1 mM DTT, 3 mM Mg2Cl and
protease inhibitor cocktail (Roche)). Cells were incubated for 10 min on ice before
passaging through a needle 10 times. NaCl was added to a final concentration of
300 mM, and the lysate was rotated at 4 1C for 20 min. After centrifugation for 5 min
at 2500 g at 4 1C, the supernatant was transferred to a new tube. The pellet
containing insoluble proteins was resuspended in 300-ml lysis buffer B (10 mM
Hepes-KOH (pH 7.4), 300 mM NaCl, 1 mM DTT, 20 mM Mg2Cl, 0.2 U DNase and
Protease Inhibitor cocktail (Roche)) and incubated for 30 min at 37 1C. The
extract was centrifuged at 2500 g at 4 1C for 5 min, and the supernatant was
combined with the soluble protein fraction. Protein extracts (30mg) were
separated on a 10% SDS gel, transferred to a polyvinylidene difluoride (PVDF)
membrane and immunoblot analyses were performed with the aforementioned
antibodies.
For immunofluorescence, cells were seeded on cover slips and cultivated at 37 1C.
After treatment, cells were fixed with 100% methanol at  20 1C and incubated with
antibodies against NRF2 (1 : 100 in PBS) overnight at 4 1C followed by an incubation
with Alexa-fluor 594-labeled secondary antibody. Analysis of subcellular localizations
was performed using a confocal fluorescence microscope (LSM 510 meta, Zeiss,
Jena, Germany), and image analysis was carried out with the Axio vision software
(Zeiss).
ChIP and illumina sequencing (ChIP-Seq). ChIP was done according
to the protocol of Dahl et al.54 Briefly, immediately before harvesting the cells
sodium butyrate (Sigma-Aldrich) was added to the cell culture medium to a final
concentration of 20 mM and mixed gently. The cells were harvested by trypsinization
and cross-linked with 1% (v/v) formaldehyde for 10 min at room temperature. The
cross-link reaction was stopped by adding glycine to a final concentration of 125 mM
for 5 min. Cells were lysed with lysis buffer (50 mM Tris-HCl, 10 mM EDTA, 1% SDS,
protease inhibitor cocktail and 20 mM sodium butyrate). The chromatin was sheared
by sonication to a DNA fragment size of 200–600 bp and precipitated by
centrifugation at 12 000 g at 4 1C for 10 min. For immunoprecipitations, 5mg of
each antibody or of a rabbit immunglobulin G (IgG) control were incubated overnight
with the sheared DNA. The next day, 50ml protein G Dynabeads (Life Technologies)
were added and incubated for 4 h at 4 1C. The antibody/chromatin/beads complexes
were washed four times with RIPA buffer (10 mM Tris-HCl, 1 mM EDTA, 0.5 mM
EGTA, 1% Triton-X100, 0,1% SDS, 0,1% sodium-deoxycholate and 140 mM NaCl)
and once with TE-buffer (10 mM Tris-HCl, 10 mM EDTA). DNA was incubated with
elution buffer (20 mM Tris-HCl, 5 mM EDTA, 20 mM sodium butyrate, 50 mM NaCl)
containing 50mg/ml proteinase K at 68 1C for 2 h. DNA was purified using the
Qiagen MinElute columns (Qiagen). In all, 300 pg of ChIP and input DNA were
analyzed using qPCR with the following primers:
HMOX1_Prom_fw: 50-GGATTCCAGCAGGTGACATT-30 and HMOX1_Prom_
rev: 50-GTGGGCAACATCAGGAACTT-30;
HMOX1_E1_fw: 50-GAAGGCGGATTTTGCTAGATTT-30 and HMOX1_E1_rev:
50-CTCCTGCCTACCATTAAAGCTG-30;
KEAP1_Prom_fw: 50-GAAAGGAGCGGCGATTCTC-30 and KEAP1_Prom_rev:
50-TGGAAGGGACAGTGAGAAGG-30;
HDAC6_Prom_fw: 50-GCCAGTGTTTCCTGTGTACC-30 and HDAC6_Prom_rev:
50-GTTGCCACTGGACGTTGG-30;
SESN3_Prom_fw: 50-CCCTGCTCAGAAAGGAAGGT-30 and SESN3_Prom_rev:
50-TGGACGCTAAAACCCTGACT-30;
MAPK3_Prom_fw: 50-CAGGCTGGAGTGTAGTGGTG-30 and MAPK3_Prom_
rev: 50-CACTCGTAGTCCCAGCTCTT-30; and
VIM_Prom_fw: 50-GAAGAGCGAGAGGAGACCAG-30 and VIM_Prom_rev:
50-CTCCCAGATCACGATTGCAC-30.
As a negative control (NCR), the following primers were used:
NCR-fw: 50-TGCTGTTACTTTTTACAGGGAGTT-30 and NCR-rev: 50-TTTGAGC
AAAATGTTGAAAACAA-30.
The relative enrichment towards the IgG control was calculated using the
%Input method previously described.55 Sequencing libraries were prepared
according to the Illumina’s ChIP-Seq Sample Prep Kit and analyzed on the
Illumina Genome Analyzer IIx (Illumina, San Diego, CA, USA) (Supplementary
Table S7).
RNA-Sequencing (RNA-Seq) and qPCR. Total RNA was purified using
the RNA MicroPrep Kit (Zymo Research, Irvine, CA, USA). Complementary DNA
was generated using SuperScript II Reverse Transcriptase (Life Technologies)
according to the manufacturer’s instructions. The relative expression was











Library preparations were performed following the instructions of the TrueSeq
RNA Sample Preparation Kit (Illumina), and sequencing was performed on the
Illumina HighSeq 2500 (Supplementary Table S7). Validation of the RNA-Seq data
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was performed with qPCR experiments and resulted in Pearson’s correlation
coefficients of 0.86 (Supplementary Figure S2b).
Bioinformatics and statistical analysis
Primary sequencing data analysis: Sequences were generated using
Illumina’s HiSeq 2500 instrument. Fastq files were obtained after demultiplexing
using Illuminas CASAVA v1.8.2 pipeline with default parameters. All data have
been deposited in NCBI’s Gene Expression Omnibus56 and are accessible
through GEO Series accession number GSE50491.
Secondary analysis: Reads were mapped against the human genome
GRCh37/hg19 using bwa v0.5.9-r16 with default parameters.
RNA-Seq expression analysis: Exon read coverages were obtained with
coverageBed v2.17.0 using exon coordinates of the Ensembl database v63.
Transcript counts were generated by summing read counts across all exons of a
given transcript.
Expression changes were calculated as log2(ratios) of the read countsþ 1 read
per transcript for two investigated conditions, and ratios were normalized against the
median ratio of each condition.
ChIP-Seq analysis: Bam files from bwa alignments were used as input
information and peaks were called with MACS v1.457 using an enrichment ratio
against the background of 5–15 to build the model (m¼ 5,15). PeakSplitter v158
was used with default parameters to call the subpeaks. Obtained subpeaks were
subsequently annotated to TSS. In more detail, a subpeak was associated to a
promoter if at least one base of the identified peak range was within 500 bp
upstream of a TSS. We used MEME v4.6.131 with the parameters -mod zoops -
text -dna -revcomp -nostatus -nmotifs 10 -minw 8 -maxw 12 -maxsize 15 000 000
to search for enriched sequence motifs (zero or one motif per peak) in a window of
300 bp around the subpeak summit. Obtained sequence motifs were annotated to
known transcription factor-binding sites with TOMTOM31 using E-value or q-value
cutoffs of Eo0.5 or qo0.1.
Microarray expression analysis: Expression data of prostate cancer
biopsies were obtained as quantile-normalized values from the publication by
Brase et al.24 GEO database (NCBI, GEO, GSE29079). For the determination of
BRD4 expression levels, we used the core probe set of the Affymetrix human exon
1.0 ST array (Affymetrix, Santa Clara, CA, USA). The BRD4 core probes are
located at the very C-terminus of the long BRD4 isoform.
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